drugset
drugset / Trial / NCT04952467

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

NCT04952467 ↗

Phase 1 Completed 6 enrolled Xenon Pharmaceuticals Inc.
NaSingle-groupOpen-labelBasic science

Summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-XEN1101 in healthy adult male subjects.

Timeline

Start
2021-07-14
Primary completion
2021-10-04
Completion
2021-10-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azetukalner Small molecule 20 mg Oral

Indications

No indication recorded.